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Aberrant CD117 expression is associated with a favorable out-
come in multiple myeloma. We analyzed 106 patients with
symptomatic multiple myeloma (n=50), smoldering multiple
myeloma (n=38) and monoclonal gammopathy of undeter-
mined significance (n=18) to elucidate biological features of
CD117+ versus CD117– monoclonal gammopathies. CD117+
(mono)clonal plasma cells were detected in 30% symptomatic
multiple myeloma, 45% smoldering multiple myeloma and
72% monoclonal gammopathy of undetermined significance
patients. CD117 expression was associated with higher per-
centages of normal bone marrow plasma cells, CD117+
myeloid precursors and CD38+ B lymphocytes in all monoclon-
al gammopathies. Conversely, the number of bone marrow
CD34+ myeloid cells and peripheral blood neutrophils was
reduced among CD117+ multiple myeloma but not monoclonal
gammopathy of undetermined significance patients.
CD117 expression by (mono)clonal plasma cells is associated
with uniquely altered patterns of production of hematopoietic
bone marrow cells with decreased peripheral blood neutrophil
counts and persistence of normal residual bone marrow plasma
cells.
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ABSTRACT
Introduction
CD117 (ckit), a class III receptor tyrosine kinase, is normal-
ly expressed by mast cells and a subset of precursor cells in
the bone marrow.1 Despite the fact that early bone marrow B-
cell precursors might be partly CD117+ in rodents, in humans
all CD19+ B cells are typically CD117– from early bone mar-
row precursors to plasma cells.2-4 Noteworthy, aberrant
CD117 expression has sporadically been reported in patients
with B-cell non-Hodgkin´s lymphoma, but occurs  in about
30% of all multiple myeloma (MM) patients.5-7 Interestingly,
CD117 expression by (mono)clonal plasma cells confers a
favorable prognosis in multiple myeloma, albeit ckit has been
associated with oncogenic transformation in other malignan-
cies such as gastrointestinal stromal tumor and mastocytosis,
in which it may represent an important target molecule for
specific therapies (e.g. imatinib).2,6,8,9 Previous studies in sys-
temic mastocytosis and myeloid neoplasms have shown that
ckit might promote activation of pro-oncogenic regulatory
molecules such as the signal transducer and activator of tran-
scription 5.10
Based on these observations it could be hypothesized that,
more than an oncogenic receptor, CD117 expression by
(mono)clonal plasma cells could act as an adhesion molecule,
which could favor anchoring of bone marrow plasma cells to
inappropriate myeloid precursor-associated bone marrow
niches through ckit ligand expressing stromal cells. 
We investigated the impact of CD117 expression by
(mono)clonal plasma cells on bone marrow hematopoiesis in
different subtypes of monoclonal gammopathy and correlat-
ed it with other biological and cytogenetic features of the dis-
ease. Overall, our results suggest that CD117 expression by
(mono)clonal plasma cells is associated with a uniquely
altered pattern of production of hematopoietic cells con-
sisting of a decreased neutrophil production and a pre-
served normal residual bone marrow plasma cell compart-
ment.
Design and Methods
Patients and samples
Patients with newly diagnosed symptomatic multiple myeloma
(n=50), smoldering multiple myeloma (n=38) and monoclonal
gammopathy of undetermined significance (n=18) were included
in this study.11 Patients were 43% females and 57% males with a
median age of 65 years (range 39-89 years). All patients gave writ-
ten informed consent before entering this study, which was
approved by the local ethics committee.
Multiparameter flow cytometry studies, fluorescence
in situ hybridization and DNA ploidy analyses
Immunophenotyping of (mono)clonal plasma cells was carried
out in EDTA-anticoagulated, erythrocyte-lysed peripheral blood
or whole bone marrow samples with a conventional direct
immunofluorescence stain-and-then-lyse technique previously
described.12,13 For data acquisition, a standard FACSCanto II flow
cytometer equipped with the FACS Diva software (Becton
Dickinson Biosciences (BD), San José, CA, USA) was used; the
Infinicyt software (Cytognos SL, Salamanca, Spain) was used for
data analysis (Online Supplementary Appendix). Fluorescence in situ
hybridization (FISH) and DNA ploidy analyses were carried out as
previously reported (Online Supplementary Appendix).6,14
Statistical methods
Group comparisons with respect to frequencies were per-
formed with the c2 or Fisher’s exact test, while for continuous
measurements Mann-Whitney’s U test was used. Spearman´s test
was used to evaluate the correlation between quantitative vari-
ables. P values below 0.05 (two-sided) indicated statistical signifi-
cance. For all statistical analyses the commercially available PASW
software (Version 18.0, Chicago, IL, USA) was used.
Results and Discussion
Patients’ characteristics
CD117 expression occurred more frequently (P=0.004)
in monoclonal gammopathy of undetermined significance
(72%) than in smoldering (45%) or symptomatic multiple
myeloma (30%). No statistically significant differences
were found among the three different patient groups as
regards the median percentage of CD117+ (mono)clonal
plasma cells among CD117+ cases. There was no signifi-
cant difference in either the median age nor the distribu-
tion by sex or the International Staging System stages
between CD117+ and CD117– multiple myeloma patients
(data not shown). The fact that CD117 expression by
(mono)clonal plasma cells decreased from monoclonal
gammopathy of undetermined significance to smoldering
and symptomatic multiple myeloma in our series supports
the hypothesis that its expression is related to the aggres-
siveness and/or prognosis of the underlying monoclonal
gammopathy.6
In this regard, immunoglobulin heavy chain (IGH)
translocations were more common among CD117– versus
CD117+ patients in all three subgroups of monoclonal
gammopathy and high-risk karyotypes were prevailing in
CD117– versus CD117+ multiple myeloma patients (Table
1) with a similar distribution in symptomatic versus smol-
dering multiple myeloma (data not shown).
DNA ploidy did not differ significantly between CD117–
and CD117+ multiple myeloma patients: 8 of 10 (80%) and
13 of 19 (68%) hyperdiploid cases in the absence of IGH
translocations in CD117+ versus CD117– cases (not signifi-
cant, Table 1) with comparable DNA indices (median of
1.21 versus 1.29, range 1.08-1.27 and 1.10-2.00). IgG iso-
type was prevailing in CD117+ multiple myeloma patients
(73% versus 37%, P=0.02), whereas IgA and light chain
multiple myeloma were more common in the CD117–
cohort: 13% versus 42% (P=0.06) and 7% versus 17% (not
significant). There was no significant difference in total
serum Ig levels between CD117+ versus CD117– multiple
myeloma patients, neither when considering involved nor
none-involved Igs (data not shown). Immunoparesis (serum
Ig levels decreased by more than 25% of the lower normal
values) was present in a similar proportion of CD117+
(82%) and CD117– (86%) multiple myeloma patients (not
significant).
Distribution of plasma cells and other hematopoietic
cell subsets in the bone marrow and the peripheral
blood
In vitro studies showed that different isoforms of the ckit
tyrosine kinase receptor might be induced in (mono)clonal
plasma cells by the stem cell factor and that it is efficiently
coupled to downstream pathways (e.g. the phosphoinosi-
tide-3 kinase/Akt pathway), suggesting ckit is functional
in (mono)clonal plasma cells.9,15 Despite this, preliminary
studies indicate that inhibition of CD117 by imatinib does
not show a marked effect on CD117+ versus CD117–
(mono)clonal plasma cells, neither in vivo nor in vitro.16,17
Interestingly, CD117 is rarely expressed in multiple
myeloma cell lines indicating that the interaction of the
bone marrow microenvironment and (mono)clonal plas-
Table 1. Cytogenetic abnormalities in CD117+ versus CD117– MM and MGUS
patients.
Cytogenetic MM MGUS
abnormality/ CD117+ CD117- P value CD117+ CD117- P value
DNA ploidy status (n=19) (n=42) (n=9) (n=5)
IGH translocations
None 17 (90) 22 (52) 0.008* 8 (89) 3 (60) NS
t(4;14) 1 (5) 7 (17) NS 0 0 NS
t(11;14) 0 5 (12) NS 0 2 (40) NS
t(14;16) 0 2 (5) NS 0 0 NS
Other 1 (5) 6 (14) NS 1 (11) 0 NS
Del(13q) 6 (32) 17 (40) NS 3 (33) 3 (60) NS
Del(17p) 0 2 (5) NS 0 0 NS
High-risk, any 1 (5) 11 (26) 0.08 0 0 NS
t(4;14), t(14;16) 
or del(17p)
Ploidy**
Hypodiploid 0 1 (2.5) NS
Diploid 6 (40) 13 (32.5) NS NT NT Not 
applicable
Hyperdiploid 9 (60) 26 (65) NS
Results expressed as number of cases and percentage between brackets. *these differences
remained significant if considering only symptomatic MM patients (100% versus 52%, P=0.01).
**evaluated in 15 CD117+ and 40 CD117- MM patients. MGUS (monoclonal gammopathy of
undetermined significance), MM (multiple myeloma), NS (not significant), NT (not tested).
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ma cells might also play a relevant role in the regulation of
CD117 expression in these diseases.2,16 Therefore, it could
be hypothesized that, more than an oncogenic receptor,
CD117 expression by (mono)clonal plasma cells could
have other functional roles and act, for example, as an
adhesion molecule. This could favor anchoring of
(mono)clonal plasma cells to inappropriate myeloid pre-
cursor-associated niches in the bone marrow.
In this regard, our results showed significantly higher
median percentages of residual normal plasma cells,
CD117+ precursors and CD38+ B cells in the bone marrow
of CD117+ versus CD117– multiple myeloma (Table 2).
Conversely, CD34+ myeloid hematopoietic progenitor
cells tended to be lower in CD117+ versus CD117– multiple
myeloma patients, leading to a significantly decreased
median ratio between CD34+/CD19– myeloid and
CD34+/CD19+ lymphoid progenitors and a significantly
increased median ratio between CD117+ precursors and
CD34+/CD19– myeloid progenitors in CD117+ versus
CD117– multiple myeloma patients (Table 2). These differ-
ences were likewise observed in symptomatic and smol-
dering multiple myeloma when both patient groups were
analyzed separately (data not shown). CD117 expression by
(mono)clonal plasma cells was further associated with a
significantly (P=0.02) decreased percentage of bone mar-
row neutrophils in symptomatic multiple myeloma
patients (median 38%, range 17%-67% versus median
50%, range 13%-72%). 
In line with these observations, CD117 expression by
(mono)clonal plasma cells was associated with a signifi-
cantly lower number of peripheral blood neutrophils in
multiple myeloma patients (median 2.5 versus 2.9¥109/L,
P=0.04) leading to a substantially lower median ratio
between the number of peripheral blood neutrophils and
the percentage of CD117+ precursors in CD117+ multiple
myeloma (1.2 versus 2.1, P<0.001; Online Supplementary
Tables S1 and S2). Thus, an inverse correlation was found
in multiple myeloma between the percentage of bone
marrow CD117+ (mono)clonal plasma cells and the num-
ber of peripheral blood neutrophils (r=-0.39, P=0.003,
Figure 1), whereas the percentage of bone marrow
CD117+ precursors positively correlated with the percent-
age of bone marrow CD117+ (mono)clonal plasma cells
(r=0.31, P=0.003). Taken together, these results suggest
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Table 2. Distribution of bone marrow cell subsets in CD117+ versus CD117- MM and MGUS patients. 
Cell subset MM MGUS
CD117+ (n=32) CD117- (n=56) P value CD117+ (n=13) CD117- (n=5) P value
% of BM PC 4.8 (0.2-63.0) 4.8 (0.1-68.0) NS 0.6 (0.2-4.1) 1.3 (0.3-4.8) NS
M-PC* 100 (67-100) 100 (80-100) 0.02 61 (6-96) 100 (78-100) 0.03
N-PC* 0 (0-33) 0 (0-20) 0.02 39 (4-94) 1 (0-22) 0.03
Ratio N-PC/M-PC* 0 (0-0.50) 0 (0-0.25) 0.02 0.64 (0.04-15.67) 0 (0) 0.03
% of BM CD117+ precursors 1.84 (0.39-3.49) 1.29 (0.19-3.34) 0.02 2.01 (0.61-3.61) 0.87 (0.57-3.65) NS
CD117+ neutrophil precursors** 34 (12-64) 38 (10-66) NS 39 (20-60) 36 (27-39) NS
CD117+ erythroid precursors** 33 (11-55) 37 (15-58) 0.06 30 (18-36) 25 (18-33) NS
% of BM mast cells 0.001 (0-0.030) 0 (0-0.034) NS 0.007 (0-0.173) 0.004 (0-0.012) NS
% of BM CD34+ HPC 0.36 (0.03-1.21, 9) 0.44 (0.05-1.04, 15) NS NT NT not applicable
CD34+ myeloid HPC*** 57 (0-69, 10) 66 (0-81, 16) NS NT NT not applicable
CD34+ lymphoid HPC*** 13 (0-31, 10) 8 (0-32, 16) 0.07 NT NT not applicable
CD34+ immature HPC*** 31 (15-100, 10) 29 (0-46, 16) NS NT NT not applicable
CD34+ myeloid/ lymphoid HPC ratio*** 4.3 (1.2-7.3, 9) 7.9 (1.4-66.0, 13) 0.04 NT NT not applicable
BM CD117+ precursors/BM CD34+ 8.8 (2.4-17.5, 15) 3.8 (1.0-6.9, 15) 0.001 NT NT not applicable
myeloid HPC ratio
% of BM neutrophils 48 (17-74) 53 (13-79) 0.10 64 (37-72) 59 (44-70) NS
% of BM lymphocytes 19 (8-48) 18 (6-39) NS 12 (7-19) 13 (9-18) NS
% of BM B cells 1.8 (0.2-18.9) 2.0 (0.2-5.6) NS 1.6 (0.4-5.7, 12) 1.5 (1.1-1.9) NS
Pro-B cells**** 3 (0-23, 18) 5 (0-10, 20) NS 4 (0-13, 12) 0 (0-7) 0.06
Pre-B cells**** 14 (1-65, 18) 17 (0-32, 20) NS 16 (0-44, 12) 3 (1-14) 0.03
Mature B cells**** 84 (28-100, 18) 78 (65-100, 20) NS 80 (43-100, 12) 97 (79-99) 0.04
CD38+ B cells**** 27 (0-85) 20 (0-65) 0.02 27 (3-62, 12) 10 (1-23) 0.03
Results expressed as median percentage (range, number of evaluable patients if data are missing) of all BM cells or BM PC*, BM CD117+ precursors**, BM CD34+ HPC*** and BM
CD19+ B cells****.  BM (bone marrow),  HPC (hematopoietic progenitor cells),  MGUS (monoclonal gammopathy of undetermined significance),  MM (multiple myeloma),  M-PC
[(mono)clonal plasma cells],  N-PC (normal plasma cells),  NS (not significant), NT (not tested).
Figure 1. Correlation between the percentage of CD117+ bone mar-
row (mono)clonal plasma cells and peripheral blood neutrophil
counts in MM. M-PC [(mono)clonal plasma cells], N. (number), PB
(peripheral blood).
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that neutrophil maturation in the bone marrow is consid-
erably altered in CD117+ versus CD117– multiple myeloma
patients with a lower rate of production and release of
mature neutrophils into the peripheral blood, despite pro-
gressive accumulation of early CD117+ myeloid precursors
potentially reflecting an early blockade and altered bone
marrow production of neutrophils. This could be attribut-
able to an increased consumption of stem cell factor in the
bone marrow by CD117+ (mono)clonal plasma cells; alter-
natively, it could also be associated with an altered hom-
ing of CD117+ (mono)clonal plasma cells into bone mar-
row niches. Dysregulated hematopoietic niches have
already been related to various diseases e.g. myeloprolifer-
ative syndromes and our observations led to the assump-
tion that these niches could also be altered in CD117+
monoclonal gammopathies.18 The fact that also neutrophil
lineage cells within the CD117+ precursor cell compart-
ment, CD34+ myeloid cells, and total bone marrow neu-
trophils tended to decrease in CD117+ versus CD117– mul-
tiple myeloma patients (Table 2) suggests that different
maturation-associated compartments of myeloid cells
(including the very immature cell compartments) could be
involved in the dysregulated myelopoiesis. Thus, our
observations indicate that CD117 expression by
(mono)clonal plasma cells could alter their homing and
lead to an interference with neutrophil precursor niches,
with progressively more marked downregulation of neu-
trophil production. Hereby, CD117 expression by
(mono)clonal plasma cells might act as an additional
anchor molecule, resulting in a decrease in the spread of
(mono)clonal plasma cells to the plasma cell/B-cell precur-
sor niches. In turn, this would lead to a greater mainte-
nance of the homeostatic role of residual normal plasma
cells in CD117+ versus CD117– multiple myeloma. 
In line with this hypothesis, we also found altered pat-
terns of lymphoid maturation in CD117+ versus CD117–
multiple myeloma. Accordingly, the percentage of early
bone marrow CD38+ B cells was significantly increased in
CD117+ versusCD117– multiple myeloma and also the per-
centage of CD34+CD19+ lymphoid cells tended to be high-
er in these patients (Table 2). However, the percentage of
B lymphocytes in the peripheral blood was decreased in
CD117+ versus CD117– multiple myeloma (56 versus
94¥106/L, not significant; Online Supplementary Table S1).
Since B cell precursors are exclusively CD117– in humans,
our data led to the assumption that the dysregulated
hematopoiesis in CD117+ multiple myeloma is not
restricted to the CD117+ bone marrow cell compartments,
but it also involves CD117– B cells.4
The alterations of both bone marrow myeloid and lym-
phoid maturation in CD117+ versusCD117– cases discussed
above affected both symptomatic and smoldering multiple
myeloma, but not monoclonal gammopathy of undeter-
mined significance patients. Also in these latter monoclon-
al gammopathy of undetermined significance cases, the
median percentage of bone marrow CD117+ precursors
and CD38+ B cells was higher in CD117+ versus CD117–
patients (Table 2). However, in contrast to multiple myelo-
ma, the median number of peripheral blood neutrophils
was not decreased in CD117+ (4.4¥109/L, range 3.4-
13.1¥109/L) versus CD117– (3.2¥109/L, range 2.1-4.8¥109/L)
monoclonal gammopathy of undetermined significance
patients. Altogether, these results suggest that CD117
expression by (mono)clonal plasma cells might have a
comparable impact on bone marrow myeloid and lym-
phoid maturation patterns in different subgroups of mono-
clonal gammopathies, but that the release of mature neu-
trophils into the peripheral blood would only be impaired
in multiple myeloma. Conversely, the distribution of nor-
mal versus (mono)clonal plasma cells is already altered dif-
ferentially in CD117+ versus CD117– in both multiple
myeloma and monoclonal gammopathy of undetermined
significance cases. Accordingly, the percentage of residual
bone marrow normal plasma cells was also significantly
higher in CD117+ versus CD117– monoclonal gammopathy
of undetermined significance patients (Table 2).
Recent clinical observations led to the assumption that
co-expression of CD28 by (mono)clonal plasma cells
might attenuate the positive prognostic impact of CD117
expression in multiple myeloma.6 In the present study,
CD28 expression by (mono)clonal plasma cells occurred in
11 of 32 (34%) CD117+ versus 21 of 54 (39%) CD117– mul-
tiple myeloma patients (not significant). In monoclonal
gammopathy of undetermined significance, CD28 expres-
sion was observed in 6 of 12 (50%) CD117+ versus 3 of 5
(60%) CD117– cases (not significant). CD28 co-expression
by (mono)clonal plasma cells did not have any significant
impact on any bone marrow or peripheral blood cell sub-
set in CD117+ multiple myeloma or monoclonal gam-
mopathy of undetermined significance patients (data not
shown). 
In summary, our results show that CD117 expression is
associated with characteristic biological features in differ-
ent types of monoclonal gammopathies consisting of a
uniquely altered myeloid and lymphoid maturation pat-
tern, preponderance of IgG isotype and a lower frequency
of adverse cytogenetic characteristics. These results sug-
gest that CD117 expression by (mono)clonal plasma cells
alters their homing in the bone marrow and could redirect
them into neutrophil precursor niches, where CD117
might act as an anchor molecule; such redistribution of
(mono)clonal plasma cells in the bone marrow could con-
tribute to the greater maintenance of the  homeostatic role
of residual normal plasma cells and a more limited spread
of (mono)clonal plasma cells in CD117+ monoclonal gam-
mopathies. 
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